Oruka Therapeutics, Inc. ORKA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$116.25M-10.3% | -$105.43M+33.9% | -$159.57M-1.0% | -$157.92M-1.5% | -$155.59M-9.8% | ||
| $110K+32.5% | $83K+1.2% | $82K+12.3% | $73K+28.1% | $57K+29.5% | ||
| $26.33M+8.6% | $24.24M-30.8% | $35.04M+1.1% | $34.65M+14.2% | $30.34M+18.8% | ||
| -$90.92M-3.1% | -$88.21M+28.5% | -$123.45M+12.4% | -$140.87M-9.3% | -$128.93M-19.1% | ||
| $269K+28.7% | $209K-37.6% | $335K-17.7% | $407K— | —— | ||
| -$154.05M-59.2% | -$96.75M+76.1% | -$404.85M-43.3% | -$282.57M+1.7% | -$287.43M+13.0% | ||
| —— | —— | —— | —— | —— | ||
| -$34.05M-133% | -$14.64M-116% | $91.25M-80.8% | $476.27M-6.5% | $509.57M+4.8% | ||
| -$91.19M-3.1% | -$88.42M+28.6% | -$123.79M+12.4% | -$141.28M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Oruka Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.